Legend Biotech Corporation (LEGN)

NASDAQ: LEGN · Real-Time Price · USD

18.12

-0.24 (-1.31%)

At close: Feb 20, 2026, 4:00 PM EST

20.53

+2.41 (13.30%)

Pre-market: Feb 23, 2026, 7:22 AM EST

Legend Biotech Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Operating Revenue	908.71	620.98	284.96	116.68	65.4	75
Other Revenue	0.34	6.26	0.18	0.33	3.42	-
Revenue	909.05	627.24	285.14	117.01	68.83	75
Revenue Growth (YoY)	74.76%	119.97%	143.70%	70.00%	-8.23%	21.36%
Cost of Revenue	776.37	648.13	526.43	401.01	313.35	232.16
Gross Profit	132.68	-20.88	-241.29	-284.01	-244.52	-157.16
Selling, General & Admin	323.53	284.26	200.93	174.05	149.5	72.71
Operating Expenses	323.53	284.26	200.93	174.05	149.5	72.71
Operating Income	-190.86	-305.15	-442.22	-458.05	-394.02	-229.87
Interest Expense	-19.92	-21.62	-21.79	-10.8	-0.9	-0.2
Interest & Investment Income	45.8	61.2	54.49	8.18	0.97	2.93
Currency Exchange Gain (Loss)	-55.78	108.51	-28.65	-9.88	-	0.07
Other Non Operating Income (Expenses)	3.65	3.34	-82.61	24.22	-12.27	-1.23
EBT Excluding Unusual Items	-217.1	-153.71	-520.78	-446.33	-406.22	-228.29
Gain (Loss) on Sale of Investments	-	-	0.66	0.6	-	0.05
Gain (Loss) on Sale of Assets	-	-	-	-	-0.97	-0.06
Asset Writedown	-5.39	-4.42	-	-	-	-
Other Unusual Items	-	-	-	-	-	-79.98
Pretax Income	-222.49	-158.13	-520.12	-445.72	-407.2	-308.29
Income Tax Expense	17.21	18.89	-1.86	0.63	-3.61	-41.91
Net Income	-239.7	-177.03	-518.25	-446.35	-403.58	-266.37
Net Income to Common	-239.7	-177.03	-518.25	-446.35	-403.58	-266.37
Shares Outstanding (Basic)	184	183	176	159	141	118
Shares Outstanding (Diluted)	184	183	176	159	141	118
Shares Change (YoY)	0.86%	3.84%	10.71%	12.91%	19.21%	18.15%
EPS (Basic)	-1.30	-0.97	-2.94	-2.81	-2.87	-2.25
EPS (Diluted)	-1.30	-0.97	-2.94	-2.81	-2.87	-2.26
Free Cash Flow	-188.68	-158.14	-413.36	-222.21	-240.66	-249.26
Free Cash Flow Per Share	-1.02	-0.86	-2.35	-1.40	-1.71	-2.11
Gross Margin	14.59%	-3.33%	-84.62%	-242.73%	-	-209.55%
Operating Margin	-21.00%	-48.65%	-155.09%	-391.48%	-572.49%	-306.49%
Profit Margin	-26.37%	-28.22%	-181.75%	-381.48%	-586.38%	-355.16%
Free Cash Flow Margin	-20.76%	-25.21%	-144.97%	-189.91%	-349.67%	-332.34%
EBITDA	-181.24	-294.29	-431.48	-445.41	-385.88	-223.63
EBITDA Margin	-19.94%	-46.92%	-151.32%	-	-	-298.18%
D&A For EBITDA	9.62	10.86	10.73	12.65	8.14	6.23
EBIT	-190.86	-305.15	-442.22	-458.05	-394.02	-229.87
EBIT Margin	-21.00%	-48.65%	-155.09%	-	-	-
Revenue as Reported	909.05	627.24	285.14	117.01	68.83	75

Updated Nov 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q